ClinicalTrials.gg
RecruitingNCT07629115Updated Jul 1, 2026

A Long-Term Follow-up Study of the Severe Parkinson's Disease Patients Administered the IPS101A Gene Therapy Product.

An observational study in Parkinson Disease and Parkinson's Disease, sponsored by Innopeutics Corporation. Recruiting at 1 site in South Korea. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-01.

Sponsored by Innopeutics Corporation · Observational

How we know

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
6
Ages
50 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 76 studies in Parkinson Disease with a site in Korea, Republic of — 13 open to participants now, 15 under way, 1 of them phase 3. Parkinson Disease · Korea, Republic of.

Started
2026
with 5 others
Observational
9 of 76
5 open now
Primary completion
2031-07
later than 13 of 14 live
Registered
75th of 76
by date
Lead sponsor
2 of 76
Innopeutics Corporation

Among the 76 studies in Parkinson Disease with a site in Korea, Republic of, this one is one of 6 that started in 2026, is one of 9 observational ones, reaches primary completion later than 13 of the 14 other live ones, and was the 75th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

13 of the 76 studies in Parkinson Disease with a site in Korea, Republic of are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 50 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Parkinson Disease with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the long-term safety of IPS101A and to assess the durability of efficacy in subjects who received IPS101A.

03

Conditions studied

  • Parkinson Disease
  • Parkinson's Disease

Browse trials for

Keywords

  • Adeno-associated Virus
  • Gene therapy
  • AAV
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subject with advanced Parkinson's disease who received IPS101A gene therapy in the Phase 1 clinical trial (IPS101A-10)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who were enrolled in the IPS101A-10 clinical trial and received IPS101A.
  • Subjects and/or their legally acceptable representatives who voluntarily provided written to participate in this long-term follow-up study after being fully informed of the study, and who agreed to comply with all study-related requirements.

Exclusion criteria

Exclusion Criteria

  • Subjects who decline to provide consent for participation in the long-term follow-up study, or for whom follow-up assessments are not feasible due to death or other reasons.
  • Subjects who, in the judgment of the investigator, are considered unsuitable for participation in the study due to unwillingness or inability to comply with scheduled study visits or other study-related requirements.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
6 participants (estimated)
Patient registry
No

Groups and cohorts

  • The group that received IPS101A

    The group of subjects who received IPS101A in the IPS101A-10 clinical trial

06

What researchers measure

Primary outcomes

  1. Safety Evaluation: Incidence of serious adverse events of special interest

    Assess severity and frequency serious adverse events of special interest

    Time frame: Baseline to 5 years

  2. Safety Evaluation: Incidence of serious adverse events (SAEs) and adverse events (AEs)

    Assess severity and frequency of reported adverse events

    Time frame: Baseline to 5 years

  3. Safety Evaluation: Number of participants with clinically-relevant changes in physical exams

    The results of the physical examination after administration of the clinical trial drug are compared with those before administration to determine whether clinically significant symptoms occur

    Time frame: Baseline to 5 years

  4. Safety Evaluation: Number of participants with clinically-relevant changes in laboratory test

    The clinical significance of laboratory test results after administration of a clinical trial drug is confirmed by comparing them with those before administration.

    Time frame: Baseline to 5 years

Secondary outcomes

  1. Change from Baseline in Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) scores (defined on/off)

    Each symptom is rated on a scale of 0 to 4, with higher scores indicating more severe Parkinson's disease.

    Time frame: Baseline to 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Jul 2031, 62 months after the start.

Of 60 industry-sponsored observational studies under Parkinson Disease, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 64. This study's planned 62 months is above that.

Counting every sponsor, half of 441 studies reached it within 47 months; a quarter within 22 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2026
First posted
Jun 5, 2026
StartActual
May 29, 2026
Primary completionEst.
Jul 30, 2031
CompletionEst.
Oct 30, 2031
Last update
Jul 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07629115
Lead sponsor
Innopeutics Corporation
Responsible party
Sponsor
First posted
Jun 5, 2026
Start date
May 29, 2026
Primary completion
Jul 30, 2031 (estimated)
Completion
Oct 30, 2031 (estimated)
Last update
Jul 1, 2026

Study contacts

ChoLong Park
Contact
clpark@innopeutics.com
+82-2-3499-4266
Tae-gyun Kim
Contact
contact@innopeutics.com

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion